Lots of old price targets and likely will never be hit. Company will need to do a secondary before NSS approval at the rate of enrollment. Will also need a good chunk of cash for the chronic/stem cell trial. Good luck, but I don't see this company valued at half a billion+ ($10 price target assuming 50 million total shares after next raise)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.